Valerie Bowering

Also affiliated with Princess Margaret Cancer Centre

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150.”.

A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5514

N/A

0.470DataRank · unranked

22 citations

Husam Alqaisi, David E. Cohn, Jing‐Yi Chern, Linda Duska, Andrea Jewell +15 more

Patient self-reporting of tolerability using PRO-CTCAE: A randomized double-blind placebo controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in women with platinum resistant epithelial ovarian cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5541

N/A

0.208DataRank · unranked

3 citations

Sandra A. Mitchell, Tyler Pittman, Lisa Wang, Valerie Bowering, Nisan Kavak +9 more